Avalo Therapeutics, Inc. has announced significant updates and financial results for 2024, highlighting a pivotal year marked by the acquisition of AVTX-009, a monoclonal antibody aimed at treating ...
Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) Respiratory syncytial virus (RSV) vaccine: Moderna received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results